Company Overview and News
2018-09-22 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
TCBK CAT MET HTH LBCC FIXX CRM BUSE STXB CHFC FIBH FBLV AVGO HBMD CAG SSB ABX MO SBT UMRX PRU MTZ NBHC HOMB EVRI 2914 FFIN BILI OPBK TAP ABRW OZK ACB BREW UNUM OLBK MTN JNJ GHG ALDX BWA VZ FNV EQBK LMT FB JAPAF RAD FNLC AXP 4162 ITYBF PRU CBTX JAPAY PPBI SFNC PNFP TBK CCL KO NCOM NBHOZ CARO TSC BOFIL KBH LION SPPI SMBK PACW DY LTEA BB WSBC TTEC VBTX ABCB DTEA HBNC GNPX FBPRM FBPRL FBPRO XLC FBPRN SNDX CSFL FBPRP MBIN HTWC AZN KMX ACBFF GBCI BATS SIVB KEY BOKF ASNA ABTX HTLF NKE HON TWTR AMAT CELH ROX JBL FBP IMBBY BY CHCO KDP INCY CRON FSB CCL STZ NBEV WTFCW WTFC FBMS WTFCM INTU NBHDZ GOOGL EGBN LTXB STL FBNC BA BB ONB PRGS FBK PFE IMBBF PFBC PH NEM LOXO MNST GOOG PIR RBB TLRY HWC PB BFST NCBS MKC WEED ACN FBSI BBBY DIS BMY OBNK OGE MBNC RNST ABX BOFI CMCSA SNV UBSH WTFPP CGC CADE AZN T IBOC IQ ONE MRK GNTY
Chicago, IL – September 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wintrust Financial Corporation (WTFC - Free Report) , Comerica Incorporated (CMA - Free Report) , Blue Hills Bancorp, Inc. (BHBK - Free Report) , Union Bankshares Corporation (UBSH - Free Report) and First Financial Bankshares, Inc.
NCLH UBNC REGN CY CMA BHBK UBSH LB WTFCW WTFPP WTFC ON GIII FFIN CMPWW WTFCM CSBR BSTC WIFI VSH 3772 UNB
Bond yields rose on Sep 19, extending the week’s climb, as investors took escalating trade related tensions in stride, and focused more on solid economic data and promising corporate outlook. The yield on the 10-year Treasury note, a benchmark for interest rates, has hit a four-month high. The Federal Reserve, in fact, has stepped up the pace of monetary tightening, with Chairman Jerome Powell vouching for a steady path of interest rate hikes.
UBNC CMA BHBK UBSH WTFCW LB WTFPP WTFC FFIN CMPWW WTFCM UNB 3772
Chicago, IL – September 17, 2018 – Today, Zacks Investment Ideas feature highlights Features: SVB Financial Group (SIVB - Free Report) ), Commerce Bancshares, Inc. (CBSH - Free Report) ), Blue Hills Bancorp, Inc. (BHBK - Free Report) ), National Bank Holdings Corporation (NBHC - Free Report) ) and First Financial Bankshares, Inc. (FFIN - Free Report) .
WFC WFCNP CBSH NBHC CBSHP BHBK SIVB FFIN CBCB
It’s been a decade since the collapse of Lehman Brothers, and mortgage crisis and the subsequent Great Recession are things of the past for investors, bankers and regulators now. In fact, a few years of low default rates and solid loan growth have helped bankers gain confidence. Banks now have more capital cushion, are into stable funding, are exposed to less risky businesses and are well guarded by stringent regulations.
WFCNP CBSH CY SIVB GS GLSSP WFC JBK NBHC CBSHP GSC BHBK TFG FFIN GSJ CBCB GJS
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
The Banking industry has been benefitting amid a stabilizing economy as well as higher interest rates. Further, the sector reported impressive performance in second-quarter 2018. Texas Capital Bancshares, Inc. (TCBI - Free Report) is one such stock which reported a year-over-year increase in its second quarter earnings. It remains well poised to grow, driven by continued top-line growth, improving earnings performance, along with a strong balance-sheet position.
TCBIW TCBIP TCBI BANFP ABM TCBIL BOKF FFIN BANF
Cullen/Frost Bankers, Inc.’s (CFR - Free Report) and its subsidiary, Frost bank’s ratings have been reiterated by Moody’s Investors Service, the rating arm of Moody’s Corporation (MCO - Free Report) . Further, the rating agency has maintained the company’s outlook at ‘stable’. Cullen/Frost Bankers’ long-term issuer and subordinate debt rating has been affirmed at A3, while preferred stock non-cumulative rating has been maintained at Baa2 (hyb).
MCO CFR FFIN BANF
A favorable operating backdrop with rising interest rates, lower commercial tax rate and ease in regulations should continue to support banking stocks. With this in mind, we have chosen BancFirst Corporation (BANF - Free Report) for your consideration.
FCCO FSB BANFP THFF FCCTO FFIN BANF FCCT FCCTP
Shares of HSBC Holdings plc (HSBC - Free Report) have lost 9.4% over the past three months compared with the industry’s fall of 7%. Muted revenue growth primarily led to the strained price performance. HSBC has been focused on growing the company’s market share and strengthening its digital capabilities. While, on one hand, this may bolster its revenues, on the other hand, it might result in elevated expenses.
BANFP BOKF HCS FFIN HSB 0005 HSEA HSEB HSBC BANF HBCYF
Texas Capital Bancshares Inc. (TCBI - Free Report) continues to grow organically, partly due to its balance-sheet strength. The company seems to be poised well for top-line growth, primarily driven by rise in net interest income. However, escalating expenses remains the key concern. Texas Capital has been experiencing an increasing trend in revenues for quite some time. Revenues witnessed a compound annual growth rate (CAGR) of 17.
TCBIW TXN TCBIP TCBI BANFP TCBIL BOKF FFIN BANF
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Investors focused on the Finance space have likely heard of First Financial Bankshares (FFIN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549
Greetings, ladies and gentlemen. Welcome to the Home BancShares Incorporated Second Quarter 2018 Earnings Call. The purpose of this call is to discuss the information and data provided in the quarterly earnings release issued this morning. Company presenters will begin with prepared remarks then entertain questions. [Operator Instructions]
19h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
Silicon Investor Message Boards
This table lists all message boards related to FFIN / First Financial Bankshares, Inc. on message board site Silicon Investor.
as of ET